MIMS Online

MIMS Pharma is running a short survey of pharma professionals to better understand their information needs and enhance the resources provided. Read more on MIMS Pharma buff.ly/12gjZKv

Isosorbide mononitrate 10mg immediate-release tablets are in short supply. Read more on MIMS buff.ly/mfEZ0kK

Women on HRT who are taking a GLP-1 agonist would use a levonorgestrel-releasing intrauterine device in an ‘ideal world’, GP Dr Toni Hazell has said in a new podcast. Read more on MIMS buff.ly/lM3OtbP

Severely immunosuppressed people will be eligible to receive the shingles vaccine from the age of 18 years, starting next month. Read more on MIMS buff.ly/Xa9VN6O

EURneffy has been approved for the treatment of anaphylaxis, the MHRA has announced, making it the first adrenaline nasal spray to be licensed in the UK. Read more on MIMS buff.ly/TCBGeS1

A prolonged-release preparation of melatonin (Slenyto) can now be prescribed to treat ADHD-related insomnia in children and adolescents after its licence was extended. Read more on MIMS buff.ly/mYNS2OH

‘Best-value’ meters, testing strips and lancets are now recommended by ascending price order in revised commissioning recommendations from NHS England. Read on MIMS buff.ly/CyBb0at

The company behind semaglutide expects to submit an application shortly for MHRA approval of a 7.2mg version of the drug for the treatment of obesity. Read more on MIMS buff.ly/khQOVwt

Amiodarone 200mg tablets are expected to be out of stock until early August 2025, according to a Medicine Supply Notification issued on 11th July. Read more on MIMS buff.ly/zGm0UB9

Guidelines from Primary Care Dermatology Society on the treatment of hair loss and prescribing of topical calcineurin inhibitors in primary care are now available on MIMS. Read more on MIMS buff.ly/NNdGo1g

Rates of antidepressant withdrawal syndrome may be lower than previously reported, results of a systematic review and meta-analysis suggest. Read more on MIMS buff.ly/smbilPk

Do not use desogestrel in people with a history of meningioma, the CoSRH (formerly FSRH) has advised. Read the full story on MIMS buff.ly/tGA66kr

Elinzanetant, a non-hormonal medication, has received MHRA approval for treating moderate-to-severe vasomotor symptoms (hot flushes). Read more on MIMS Pharma buff.ly/hTDf7VE

The risk of Guillain-Barré syndrome is slightly increased after RSV vaccination in older adults, analysis shows. Read more on MIMS buff.ly/pPUdNu3

The dopamine agonist pramipexole may be a clinically effective option for reducing symptoms in patients with treatment-resistant depression, a randomised controlled UK trial has found. Read more on MIMS buff.ly/RmhmXCt

The government wants more partnerships with industry to provide access to innovative treatments such as weight loss medications, it has said in its new 10-year plan for the NHS. Read more on MIMS Pharma buff.ly/MRSd6As

Catch up on news with our monthly update, featuring latest developments in the pharmaceutical industry, including the earlier NHS use of SGLT2 inhibitors for heart failure and GLP-1 agonists linked to an eye condition. Read more on MIMS Pharma buff.ly/8PTW63n

Bumetanide shortage prompts patient safety alert, betamethasone soluble tablets are unavailable, and Salamol Easi-Breathe is out of stock. Read more on MIMS buff.ly/Nuz2nGO

A single national medicine formulary will replace local formularies, with the goal of ending the postcode lottery of drug access, the government has revealed in its new 10-year plan for the NHS. Read more on MIMS buff.ly/z42p0jQ

A ready-to-use rivaroxaban oral suspension has been launched in the UK. Find out more on MIMS buff.ly/CZQiZVR